Navigation Links
Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Date:6/10/2008

PARIS, France - 11 June 2008 Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX) experienced significant improvements in the signs and symptoms of rheumatoid arthritis (RA) as well as in physical function and disease activity, with some patients achieving remission as measured by Disease Activity Score (DAS28). Findings from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies showed the efficacy of golimumab in two important populations MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumor necrosis factor (TNF)-alpha biologic therapy with ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis.

In the study, GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD), both the 50 mg and 100 mg doses of golimumab were studied in patients whose disease was active despite ongoing treatment with MTX. At week 14, 55 percent of patients receiving golimumab 50 mg plus MTX and 56 percent receiving golimumab 100 mg plus MTX achieved at least 20 percent improvement in signs and symptoms of RA (ACR 20), compared to 33 percent of patients receiving placebo and MTX (p<0.01 and p<0.001, respectively). Improvements were seen as early as first clinical assessment, which was four weeks after the first golimumab injection, and generally continued to improve over time.

"The data in this study demonstrate that golimumab is beneficial in improving numerous disease parameters, including inducing remission, in patients whose disease was active despite ongoing treatment with methotrexate," said Edward Keystone, M.D., FRCPC, dir
'/>"/>

Contact: Brian Kenney
bkenney1@cntus.jnj.com
215-620-0111
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Ky. , Sept. 18, 2014  Neogen Corporation ... has entered into a strategic agreement with Merck Animal ... Program. The Igenity Dairy Heifer Program ... essential information on the genetic potential of replacement dairy ... a calf is born, and is an excellent tool ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
(Date:9/18/2014)... OMICS Group International invites researchers, ... in the ‘Open Access Week’ by actively contributing ... Group Pharma Journals from 20-26th October, 2014. ... emerging Sciences, accelerating with a tremendous speed to ... globe. The industry is gearing with innovation and ...
(Date:9/18/2014)... a group of rare diseases that afflict skeletal ... onset hits at the fetal stage and is ... gene encoding fibroblast growth factor receptor 3 (FGFR3) ... dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia that ... often lethal, and achondroplasia (ACH), which causes stunted ...
Breaking Biology Technology:Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... Sponsors 2010 Semantic Web Challenge -- NEW YORK, November 16, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... London, involves a new class of materials called metamaterials, ... sound waves. With conventional materials, light typically travels along ... a wealth of additional flexibility to create undetectable blind ... an image can be altered or made to look ...
... 15, 2010, PRNewswire-Asia/ -- Tiens Biotech Group (USA), Inc. (the "Company" ... , today announced financial results for ... Revenue for the third quarter of 2010 was $10.4 million, ... for the nine months ended September 30, 2010 was $30.0 million, ...
Cached Biology Technology:Elsevier Sponsors 2010 Semantic Web Challenge 2Elsevier Sponsors 2010 Semantic Web Challenge 3Elsevier Sponsors 2010 Semantic Web Challenge 4Elsevier Sponsors 2010 Semantic Web Challenge 5Elsevier Sponsors 2010 Semantic Web Challenge 6Elsevier Sponsors 2010 Semantic Web Challenge 7Elsevier Sponsors 2010 Semantic Web Challenge 8Elsevier Sponsors 2010 Semantic Web Challenge 9Elsevier Sponsors 2010 Semantic Web Challenge 10Elsevier Sponsors 2010 Semantic Web Challenge 11'Space-time cloak' to conceal events revealed in new study 2'Space-time cloak' to conceal events revealed in new study 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 4Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 5Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 6Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 7Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 8Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 9
(Date:9/19/2014)... it the Jimmy Durante of dinosaurs a ... profile. The new dinosaur, named Rhinorex condrupus ... and Brigham Young University, lived in what is ... the Late Cretaceous period. , Rhinorex, which translates ... a close relative of other Cretaceous hadrosaurs like ...
(Date:9/19/2014)... A new resource unveiled today by researchers from ... College Dublin provides both experienced and aspiring researchers ... build, and operate robots made from soft, flexible ... printing, laser cutters, and other advances in manufacturing ... important field. Using principles drawn from conventional rigid ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study the ... analysis that could eventually benefit people,s health. The ... manage the energy required to produce the signals used ... generate electric signals at a rate of 500-600 discharges ... required for the electric fish are extreme, but necessary ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... Researchers have discovered a potentially important new resistance factor ... team of researchers from Canadian Blood Services, The Hospital ... Sweden have discovered that certain blood types are more ... at fending it off. A carbohydrate-containing antigen, termed ...
... of painstakingly handwritten books produced in medieval Europe still ... about when and where the majority of these works ... is using modern advances in genetics to develop techniques ... important cultural artifacts. Many medieval manuscripts were written ...
... new technologies that make it easier to sequence the ... Cancer Center have identified a series of genes that ... other. These recurrent gene fusions are thought to be ... The gene fusions discovered could potentially serve as ...
Cached Biology News:Researchers identify potential new weapon in battle against HIV infection 2DNA testing may unlock secrets of medieval manuscripts 2U-M researchers discover new genes that fuse in cancer 2
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Request Info...
Request Info...
Request Info...
Biology Products: